Top Page
AOTI, Inc.
(LSE:AOTI)
AOTI, Inc. (AOTI) vs. iShares MSCI United Kingdom ETF (EWC)
AOTI, Inc. Business Overview & Revenue Model
AOTI, Inc. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 58.36M | 43.92M | 8.86M | 889.10K |
| Gross Profit | 51.35M | 37.59M | 2.86M | 45.36K |
| EBITDA | 2.64M | -4.28M | 475.61K | 3.58M |
| Net Income | -1.76M | -8.19M | 1.74M | -86.82K |
Balance Sheet | ||||
| Total Assets | 39.54M | 21.08M | 9.35M | 1.51M |
| Cash, Cash Equivalents and Short-Term Investments | 9.34M | 778.48K | 2.56M | 220.20K |
| Total Debt | 8.92M | 12.35M | 4.45M | 805.51K |
| Total Liabilities | 22.10M | 26.99M | 5.94M | 1.25M |
| Stockholders Equity | 17.44M | -5.91M | 3.41M | 258.29K |
Cash Flow | ||||
| Free Cash Flow | -7.85M | -2.76M | 1.77M | -428.43K |
| Operating Cash Flow | -5.91M | -1.45M | 2.77M | -46.07K |
| Investing Cash Flow | -1.94M | -1.59M | -1.23M | -392.10K |
| Financing Cash Flow | 16.41M | -202.81K | 648.65K | 490.97K |
AOTI, Inc. Technical Analysis
AOTI, Inc. Peers Comparison
AOTI, Inc. Corporate Events
AOTI, Inc. announced that Richard Cotton, the Senior Independent Director, and Jane Cotton-Hall have purchased a total of 215,430 common shares, representing approximately 0.20% of the company’s issued share capital. This transaction, conducted on the London Stock Exchange, reflects confidence in the company’s market position and potential growth, potentially impacting stakeholder perceptions positively.
AOTI, Inc. announced that its Chief Financial Officer, Mr. Jayesh Pankhania, purchased a substantial number of the company’s common shares, increasing his total holdings to 405,539 shares. This transaction, conducted on the London Stock Exchange, reflects a significant personal investment in the company, potentially signaling confidence in AOTI’s market position and future prospects. The purchase was made in compliance with the Market Abuse Regulation, and it underscores the company’s commitment to transparency in its financial dealings.
AOTI, Inc. announced a trading update for the first half of 2025, reporting revenue growth of at least 18% despite facing challenges from US government initiatives affecting the healthcare sector. The company anticipates mid-teen revenue growth for the full year, with a focus on medium-term growth opportunities driven by its TWO2® therapy’s alignment with US health economic goals. Recent achievements include obtaining a Medicaid Provider ID in California, enhancing market access. AOTI is implementing organizational changes to navigate the evolving healthcare landscape and remains committed to its growth strategy, leveraging its proven clinical efficacy and cost-saving potential to drive future expansion.
AOTI, Inc. has been awarded a new Provider ID in California, the largest Medicaid state in the US, allowing it to secure insurers and obtain coverage for its TWO2® therapy. This achievement marks the third state this year where AOTI has expanded its market access, aligning with its strategy to add two to three states annually. The move is expected to support the company’s growth in 2026 and establish a strong reference site for CMS coverage, enhancing its commercial rollout strategy.
AOTI, Inc. announced the results of its Annual General Meeting held on June 25, 2025, where all ten proposed resolutions were passed, including the appointment of several new directors and the re-appointment of Grant Thornton as the company’s auditor. The meeting also saw the stepping down of Anthony Moffat from his director role, although he will continue as COO. These developments could strengthen AOTI’s leadership and operational strategies, potentially enhancing its market position and stakeholder confidence.
AOTI, Inc. has received a positive recommendation from Germany’s Federal Joint Committee (G-BA) for its TWO2® therapy, marking a significant milestone as Germany becomes the first country to grant full national reimbursement coverage. This decision is expected to enhance AOTI’s market penetration across Europe and beyond, aligning with the company’s 2025 business goals. The G-BA’s commitment to formulating reimbursement guidelines for the treatment of Diabetic Foot Ulcers (DFUs) under the German statutory health insurance system could take nine months, providing a framework for collaboration with private healthcare providers in the interim.
AOTI, Inc. announced the conclusion of its ‘distribution compliance period’ under Regulation S of the US Securities Act, allowing the removal of the ‘REG S’ designation from its securities. This development marks a significant step for the company, potentially enhancing its market positioning and accessibility for investors, as it no longer restricts the resale of securities for certain US Persons.
AOTI, Inc. announced the availability of its 2024 Annual Report and Financial Statements, along with the 2025 Notice of Annual General Meeting, on its website. The AGM is scheduled for June 25, 2025, in London, and shareholders are encouraged to vote by proxy. The announcement highlights the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting its market positioning and stakeholder relations.
AOTI, Inc., a leader in medical technology for wound healing, will present at the AJ Bell and Shares Spotlight Event in London on May 20, 2025. The presentation, led by CEO Dr. Mike Griffiths, will provide an overview of the company’s operations and innovations. This event highlights AOTI’s commitment to engaging with investors and stakeholders, potentially enhancing its market presence and investor relations.
AOTI, Inc. announced that its Chief Financial Officer, Jayesh Pankhania, purchased 31,250 common shares, increasing his stake to 0.03% of the company’s issued share capital. This transaction, conducted on the London Stock Exchange, reflects confidence in the company’s market position and potential growth, potentially impacting stakeholder perceptions positively.
AOTI, Inc. announced that its Non-executive Chairman, Mr. Douglas Lefort, has purchased 31,094 common shares, increasing his total holding to 1,482,715 shares, which represents approximately 1.39% of the company’s issued share capital. This transaction, conducted on the London Stock Exchange, reflects a significant investment by a key company leader, potentially signaling confidence in the company’s strategic direction and future performance.